Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Bleeding
Systematic review	7028 people with peripheral arterial disease 5 RCTs in this analysis	Proportion of people with a major bleed 50/3561 (1%) with antiplatelet agents other than aspirin 68/3467 (2%) with aspirin	OR 0.73 95% CI 0.51 to 1.06 The number of events was likely to have been too low to detect a clinically important increase in major bleeding		Not significant
RCT	3096 people with symptomatic or asymptomatic peripheral arterial disease	Proportion of people with minor bleeding 26 months 531/1545 (34%) with clopidogrel plus aspirin 323/1551 (21%) with placebo plus aspirin	HR 1.99 95% CI 1.69 to 2.34 P <0.001	Small effect size	Placebo plus aspirin
RCT	3096 people with symptomatic or asymptomatic peripheral arterial disease	Proportion of people with a fatal bleed 26 months 7/1545 (0.5%) with clopidogrel plus aspirin 6/1551 (0.4%) with placebo plus aspirin	HR 1.17 95% CI 0.39 to 3.49 P = 0.776		Not significant
RCT	3096 people with symptomatic or asymptomatic peripheral arterial disease	Proportion of people with a primary intracranial haemorrhage 26 months 3/1545 (0.2%) with clopidogrel plus aspirin 6/1551 (0.4%) with placebo plus aspirin	HR 0.50 95% CI 0.12 to 2.01 P = 0.507		Not significant
RCT	3096 people with symptomatic or asymptomatic peripheral arterial disease	Proportion of people with severe bleeding 26 months 26/1545 (1.7%) with clopidogrel plus aspirin 27/1551 (1.7%) with placebo plus aspirin	HR 0.97 95% CI 0.56 to 1.66 P = 0.90		Not significant
RCT	3096 people with symptomatic or asymptomatic peripheral arterial disease	Proportion of people with moderate bleeding 26 months 38/1545 (3%) with clopidogrel plus aspirin 29/1551 (2%) with placebo plus aspirin	HR 1.32 95% CI 0.81 to 2.16 P = 0.26		Not significant